Ideaya biosciences and hengrui pharmaceuticals announce oral presentation at iaslc 2025 world conference on lung cancer for ide849 (shr-4849), a potential first-in-class dll3-top1 adc

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (sclc) patients in hengrui's ongoing, multi-site, open label phase 1 trial data will include patients from the dose escalation and at multiple expansion doses u.s. phase 1 trial of ide849 in sclc patients initiated in 3q 2025 jiangsu, china and south san francisco, calif. , july 22, 2025 /prnewswire/ -- ideaya biosciences, inc. (nasdaq: idya), a leading precision medicine oncology company, and jiangsu hengrui pharmaceuticals co., ltd.
TOP Ratings Summary
TOP Quant Ranking